A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector

Phase 1

Not yet recruiting

• Conditions: Health Volunteer
• Interventions: Drug: JS005

• Registration Number: NCT06732973
• Lead Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Brief Summary

This study is a single-center, randomized, open-label, single-dose, parallel-controlled trial design conducted in healthy adult subjects. After signing the informed consent form and completing the screening examination, if the subjects meet all the inclusion criteria and do not meet any exclusion criteria, they will be randomly assigned to treatment group A or treatment group B: treatment group A receives a single subcutaneous injection of JS005 300 mg through PFS, and treatment group B receives a single subcutaneous injection of JS005 300 mg through AI. Subjects were followed up until the 85th day of the study to evaluate the pharmacokinetic equivalence of JS005. 136 subjects are planned to be included in each group.

The entire study cycle includes a screening period of up to 21 days and a follow-up period of 12 weeks (85 days). Subjects will be admitted to the Phase I clinical research ward on the day before administration (D-1), and can only leave after completing all examinations and evaluations on the 11th day after administration. They will return to the clinical research center for follow-up on days 15, 22, 29, 43, 57, 71, and 85.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-02
• Study First Submitted QC: 2024-12-12
• Last Update Submitted: 2024-12-12
• Study First Posted: 2024-12-13
• Last Update Posted: 2024-12-13
• Study Start: 2024-12-20
• Primary Completion: 2025-06-06
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 272

Inclusion Criteria

Not provided

Exclusion Criteria

• Previously used Secukinumab, Ixekizumab, Brodalumab, and other targeted drugs that directly act on IL-17 or IL-17 receptors.
• Any medication used within 2 weeks before randomization or the medication used on the day of randomization is still in the elimination period (within 5 half-lives), based on the length of time (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.; excluding topical medication, female contraceptives, and regular vitamins);
• Those who have participated in any clinical trial of a drug or medical apparatus within 3 months before randomization, or those who are still in the follow-up period of a clinical study or within 5 half-lives of the trial drug (whichever is longer) before randomization. Participants in clinical trials are defined as those who have given informed consent to the clinical trial and have used the trial drug (including placebo) or the trial medical apparatus.
• Have a history of allergies to any research drug ingredients. Known allergies or hypersensitivity reactions to any biological therapy during screening, if participating in this study, will pose unacceptable risks to the subjects.
• Individuals with clear diseases of the Central Nervous System, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, endocrine and metabolic systems, etc. that require medical intervention or other diseases that are not suitable for clinical trials (such as a history of mental illness, etc.) (within 5 years before screening).
• Those who have a history of blood donation in the past month, or have suffered severe blood loss (total blood volume ≥ 400 mL), or have received blood transfusions in the past 2 months.
• Within the first three months of randomization, smokers and alcoholics (drinking 14 units of alcohol per week: 1 unit = 360 mL of beer, or 45 mL of Baijiu, or 150 mL of wine; smoking > 5 cigarettes per day).
• History of Drug Abuse, or positive urine drug screening test during the screening period;
• Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), Treponema pallidum antibody and acquired immunodeficiency syndrome (HIV) antibody positive;
• The medical history, symptoms, and examination results of the subjects suggest active or latent tuberculosis. The tuberculosis status of all subjects will be screened through gamma interferon release test (IGRA) and chest X-ray.Those who test positive for IGRA will be excluded.If the IGRA result is uncertain, re-testing is allowed. Subjects with uncertain results from both tests will be excluded from the study.Subjects who underwent IGRA and X-ray examinations within one month before randomization may not undergo IGRA and X-ray examinations again during the screening period, according to the researcher's judgment.
• Randomized individuals who have had severe trauma or undergone major surgery within the previous 6 months, or plan to undergo surgery during the trial period.
• Screening or base line vital signs, physical examination, clinical laboratory examination [blood routine, blood biochemistry, urine routine, coagulation function, gamma interferon release test (IGRA), blood pregnancy], electrocardiogram examination, abdominal B-ultrasound, chest X-ray examination with abnormalities and clinical.
• Random pre-glomerular filtration rate (eGFR) < 90 mL/min/1.73m2
• Random pre-alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma-glutamyltransferase (GGT) exceeding 2 times ULN, or total bilirubin exceeding 1.5 times ULN
• Those with abnormal and clinically significant results in the first 12-lead electrocardiogram (e.g. male QTcF > 450ms, female QTcF > 470 ms; QTcF correction calculation using Fridericia formula, Fridericia formula: QTcF = QT/(RR ^ 0.33), RR is the standardized heart rate value, obtained by dividing 60 by heart rate).
• Pregnant or lactating women or male subjects whose spouses have pregnancy plans during the study period.
• Subjects who have been vaccinated or exposed to any live or attenuated vaccine within the previous 6 weeks of randomization, or who are expected to receive the above vaccines during study treatment or within 8 weeks after study drug discontinuation.
• Researchers believe that there are other factors that are not suitable for participating in the experiment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental：JS005 AI	JS005	The drug was administered by a single subcutaneous injection via AI
Experimental：JS005 PFS	JS005	The drug was administered by a single subcutaneous injection via PFS

Primary Outcome Measures

Name	Time	Method
AUC0-last	85 days	Area under the time-concentration curve from time 0 to last time of quantifiable concentration
Cmax	85 days	Maximum Concentration
AUC0-inf	85 days	Area under the time-concentration curve from time 0 to inf of quantifiable concentration

Secondary Outcome Measures

Name	Time	Method
Vz/F	85 days	Apparent volume of distribution of JS005
ADA	85 days	Incidence of anti-JS005 drug antibodies (ADA)
ADA-positive	85 days	Titers of ADA-positive samples
T1/2	85 days	Elimination half-life of JS005
incidence and severity of adverse events(AE)	85 days	incidence and severity of adverse events(AE)
The time to reach Cmax （Tmax）	85 days	Pharmacokinetic (PK) parameters of JS005 :The time to receive reach Cmax （Tmax）
Apparent clearance(CL/F)	85 days	Apparent clearance(CL/F) of JS005 :apparent clearance(CL/F)
NAb	85 days	Incidence of neutralizing antibodies (NAb)

Trial Locations

Locations (1)

Zhengzhou Sixth People's Hospital; 🇨🇳 Zhengzhou, Henan, China